tiprankstipranks
Advertisement
Advertisement

DYN Stock Latest News

Dyne Therapeutics Expands Hercules Debt Facility for Flexibility
Company AnnouncementsDyne Therapeutics Expands Hercules Debt Facility for Flexibility
4d ago
8K
DYN
Dyne Therapeutics Expands Share Authorization After Stockholder Approvals
PremiumCompany Announcements
Dyne Therapeutics Expands Share Authorization After Stockholder Approvals
13d ago
8K
DYN
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe Fly
Acting FDA head vows to block political interference, Endpoint News says
17d ago
AZN
BMY
Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum
PremiumRatings
Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum
18d ago
DYN
Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen
PremiumThe Fly
Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen
18d ago
DYN
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy
PremiumCompany AnnouncementsDyne Fully Enrolls ACHIEVE Trial for DM1 Therapy
18d ago
8K
DYN
FDA issues draft guidance to help accelerated cell, gene therapies for patients
Premium
The Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
19d ago
AZN
BMY
Analyst Lifts Dyne Price Target to $47 on Strong DMD Execution, Phase 3 Progress and Expanding Exon-Skipping Pipeline
Premium
Ratings
Analyst Lifts Dyne Price Target to $47 on Strong DMD Execution, Phase 3 Progress and Expanding Exon-Skipping Pipeline
25d ago
DYN
Dyne Therapeutics announces submission of BLA to U.S. FDA for z-rostudirsen
PremiumThe Fly
Dyne Therapeutics announces submission of BLA to U.S. FDA for z-rostudirsen
26d ago
DYN
Analyst Maintains Buy Rating on Dyne, Keeps $50 Price Target on Strength of FORZETTO Study Design and Z‑Rostudirsen Data
PremiumRatings
Analyst Maintains Buy Rating on Dyne, Keeps $50 Price Target on Strength of FORZETTO Study Design and Z‑Rostudirsen Data
1M ago
DYN
Dyne Therapeutics initiates FORZETTO trial of zeleciment rostudirsen
PremiumThe Fly
Dyne Therapeutics initiates FORZETTO trial of zeleciment rostudirsen
1M ago
DYN
Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI
PremiumThe Fly
Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI
1M ago
DYN
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
PremiumThe FlyBiogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
1M ago
DYN
ALEC
Dyne Therapeutics price target raised to $24 from $23 at Bernstein
Premium
The Fly
Dyne Therapeutics price target raised to $24 from $23 at Bernstein
1M ago
DYN
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
Premium
The Fly
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
1M ago
AZN
BMY
Trump Trade: U.S. plans AI security order without required model tests
PremiumThe Fly
Trump Trade: U.S. plans AI security order without required model tests
1M ago
DYN
RNA
Trump approves plan to fire FDA head Marty Makary, CBS reports
PremiumThe Fly
Trump approves plan to fire FDA head Marty Makary, CBS reports
1M ago
DYN
RNA
Dyne Therapeutics reports Q1 EPS (73c), consensus (78c)
PremiumThe Fly
Dyne Therapeutics reports Q1 EPS (73c), consensus (78c)
1M ago
DYN
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
PremiumRatings
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
2M ago
DYN
Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1
PremiumCompany AnnouncementsDyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1
2M ago
DYN
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
Premium
The Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
2M ago
DYN
RNA
Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data
Premium
Ratings
Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data
3M ago
DYN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >